Estados Unidos · Plataformas y datos · The Motley Fool

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Publicado por The Motley Fool · Estados Unidos hace 1 h

The company's gene-editing-focused platform looks promising.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double